Related Experiment Video

Updated: Aug 22, 2026

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
10:10

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

Platelet glycoprotein IIb/IIIa inhibition and its clinical use

Fengyang Huang1, Enrique Hong

  • 1Departamento de Farmacobiología, Calz. de los Tenorios No.235, CINVESTAV-IPN, Col. Granjas Coapa, 14330, Mexico, DF, Mexico. f_y_huang@yahoo.com

Current Medicinal Chemistry. Cardiovascular and Hematological Agents
|August 24, 2004
PubMed

Insights

Platelet activation drives vascular diseases, making glycoprotein (GP) IIb/IIIa antagonists key targets for anti-thrombotic drugs. Approved antagonists like abciximab, eptifibatide, and tirofiban offer potent anti-platelet effects by blocking final aggregation pathways.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Molecular Biology

Background:

  • Platelet activation and aggregation are central to cardiovascular, cerebrovascular, and peripheral vascular diseases.
  • Platelet adhesion and aggregation are critical targets for developing anti-thrombotic therapies.

Purpose of the Study:

  • To review the molecular biology of the glycoprotein (GP) IIb/IIIa receptor.
  • To discuss the development, characteristics, and clinical applications of GP IIb/IIIa antagonists.

Main Methods:

  • Review of existing literature on GP IIb/IIIa receptor biology and antagonists.
  • Analysis of approved GP IIb/IIIa antagonists (abciximab, eptifibatide, tirofiban) and ongoing developments.
  • Examination of clinical trial data, adverse effects, and cost-effectiveness.

Main Results:

  • GP IIb/IIIa antagonism effectively inhibits the final common pathway of platelet aggregation.
  • Three GP IIb/IIIa antagonists are FDA-approved: abciximab, eptifibatide, and tirofiban.
  • Ongoing development includes nonpeptide oral GP IIb/IIIa antagonists.

Conclusions:

  • GP IIb/IIIa antagonists represent a significant advancement in anti-thrombotic therapy.
  • Understanding receptor interactions, specificity, and adverse effects (bleeding, thrombocytopenia) is crucial.
  • Future research directions aim to optimize efficacy and safety profiles of these agents.

More Related Videos

Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...